CureSee

Puneet, Jatin Kaushik, and Amit Sahni are Season 2's most clinically pioneering AI medical technology founding team three entrepreneurs who identified that Amblyopia (lazy eye) had a 70-year-old treatment approach (patching the stronger eye to force the weaker eye to work) that had not been meaningfully updated since the 1940s, and that AI-based personalised adaptive therapy could achieve significantly better clinical outcomes with significantly better patient compliance than the conventional patching method. CureSee has received awards and support from the Government of India and claims to have successfully treated over 2,500 patients at the time of their pitch. They also have one published research paper supporting their claims of vision correction, with two more research projects in progress.

CureSee is the world's most technically advanced amblyopia treatment platform using AI to deliver personalised vision therapy through software rather than the conventional patching method, providing interactive visual exercises that adapt to each patient's specific vision deficit profile, monitoring progress in real time, and adjusting the therapy protocol to maximise clinical outcomes. The SaaS delivery model allows patients to use the software at home, dramatically improving compliance versus clinic-based patch therapy. Cure See Business is the world's first and most advanced AI-based vision therapy software built on SaaS (Software as a Service) technology.

Amount Asked: ₹50 lakhs Equity Offered: 2.5% Implied Pre-Money Valuation: ₹20 crore

Puneet, Jatin, and Amit opened Season 2 Episode 34 with the most medically specific vision care pitch in the show's history addressing Amblyopia (lazy eye) specifically, explaining why the 70-year-old patching treatment was both uncomfortable and suboptimal, and demonstrating how AI-adaptive software therapy could outperform conventional methods in both patient compliance and clinical outcomes. The pitch's most commercially significant moment was not the product demonstration but what followed: It made Namita Thapar and Peyush Bansal fight for getting the deal done. They both wanted to invest after hearing the pitch and started explaining their visions of the AI-based vision therapy company. In doing so, Bansal negates each of Thapar's visions for the pitchers, leading to both of them cross-questioning one another.

Aman Gupta was impressed but ultimately deferred to the medical domain specialists (Namita) and eyecare domain specialist (Peyush) recognising that the specific strategic value of the investment was more aligned with their domains than with boAt's consumer electronics expertise. Vineeta Singh was interested but similarly deferred to the domain specialists beauty brand expertise has no specific application to AI vision therapy clinical distribution. Anupam Mittal was intrigued by the technology but felt the domain expertise advantage belonged to Namita and Peyush. Namita Thapar was the most clinically aggressive Shark her Emcure Pharmaceuticals background in clinical distribution, hospital relationships, and healthcare marketing gave her the most immediately applicable commercial leverage for CureSee's B2B hospital distribution model. Peyush Bansal was the most domain-strategically aligned Shark Lenskart's business is literally vision correction, making CureSee's AI vision therapy an adjacent category that Lenskart's ophthalmologist and optometrist network could distribute immediately.

After a continuous deal war, team CureSee chose Mr. Peyush Bansal as their investor. Peyush invested ₹50 lakhs in CureSee for a total of 10% equity. The founders asked for ₹50 lakhs for 2.5% equity (₹20 crore valuation). Peyush ultimately offered and closed at ₹50 lakhs for 10% equity (₹5 crore valuation). The founders accepted Peyush's offer choosing the Lenskart eye care ecosystem integration over Namita's pharmaceutical hospital distribution model, specifically because Lenskart's direct-to-consumer and optometrist network was more aligned with CureSee's B2B software-through-eyecare-provider distribution model.

Puneet, Jatin Kaushik, and Amit Sahni accepted Peyush Bansal's offer of ₹50 lakhs for 10% equity at ₹5 crore valuation a significant markdown from the founders' ₹20 crore implied ask, but with the most strategically aligned investor available: Lenskart's founder, whose vision correction retail network was the most direct possible distribution channel for an AI vision therapy platform. The deal was confirmed and formally closed after the episode aired.

CureSee continues operating with the Peyush Bansal investment supporting its hospital and eyecare clinic B2B distribution expansion. The integration with Lenskart's ophthalmologist and optometrist network gives CureSee the most commercially concentrated access to the specific healthcare providers who treat Amblyopia patients the primary channel for software subscription conversion. The free eye screening on the CureSee website continues to operate serving as both a consumer awareness tool (first touch in the patient journey) and a lead generation mechanism (converting free screening users into paid therapy subscribers through hospital-referred B2B pathways).